• Publication & Reference: New therapeutic options for IBS: the role of the first in class mixed mu-opioid receptor agonist and delta-opioid receptor antagonist (mudelta) eluxadoline. Expert Rev Gastroent. 2017;11(4):285-92.
  • DOI: 10.1080/17474124.2017.1298442
  • Author(s): Corsetti M, Whorwell P.
Research Theme | Gastrointestinal & Liver

Publication & Reference

New therapeutic options for IBS: the role of the first in class mixed mu-opioid receptor agonist and delta-opioid receptor antagonist (mudelta) eluxadoline. Expert Rev Gastroent. 2017;11(4):285-92.

DOI

10.1080/17474124.2017.1298442

Author(s)

Corsetti M, Whorwell P.
Back to all publications

Website by Volute